Truist Securities Maintains Buy on Editas Medicine, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Editas Medicine (NASDAQ:EDIT) but lowers the price target from $20 to $12.
August 08, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities analyst Joon Lee maintains a Buy rating on Editas Medicine but lowers the price target from $20 to $12.
The maintained Buy rating suggests continued confidence in the company's long-term prospects. However, the lowered price target indicates a more cautious short-term outlook, likely due to recent performance or market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100